Cargando…

Role of postmastectomy radiotherapy in early-stage (T1–2N0–1M0) triple-negative breast cancer: a systematic review

Triple-negative breast cancer (TNBC), which represents 15%–20% of all breast cancers, is defined by the absence of estrogen receptor (ER) and progesterone receptor (PR) and overexpression of human epidermal growth factor receptor 2 (HER2). Owing to the absence of specific therapeutic targets and its...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Fengxia, Pu, Feifei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388262/ https://www.ncbi.nlm.nih.gov/pubmed/28435291 http://dx.doi.org/10.2147/OTT.S123803

Ejemplares similares

Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer
por: Xia, Lin-Yu, et al.
Publicado: (2022)

Outcomes in Patients with pT3N0M0 Breast Cancer with and without Postmastectomy Radiotherapy
por: Li, Chunyan, et al.
Publicado: (2021)

Comparison of long-term results between radiotherapy after breast-conserving surgery and postmastectomy radiotherapy in stage T1-2N1M0 breast cancer
por: Lan, Xiao-Wen, et al.
Publicado: (2019)

Effects of postmastectomy radiotherapy on survival in different age groups for patients with T3N0M0 breast cancer
por: He, Meng-Ting, et al.
Publicado: (2021)

Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer
por: Zhai, Zhen, et al.
Publicado: (2020)

The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer
por: Zhang, Lei, et al.
Publicado: (2020)

Effect of tumor-infiltrating lymphocytes depending on the presence of postmastectomy radiotherapy on the prognosis in pT1-2N1M0 breast cancer
por: Zhang, Lina, et al.
Publicado: (2023)

The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy
por: Fu, Wen-Fen, et al.
Publicado: (2020)

Locoregional recurrence-associated factors and risk-adapted postmastectomy radiotherapy for breast cancer staged in cT1-2N0-1 after neoadjuvant chemotherapy
por: Wang, Xin, et al.
Publicado: (2018)

Risk-Adapted Postmastectomy Radiotherapy Decision Based on Prognostic Nomogram for pT1-2N1M0 Breast Cancer: A Multicenter Study
por: Li, Ming, et al.
Publicado: (2020)

Predictive Value of Molecular Subtyping for Locoregional Recurrence in Early-Stage Breast Cancer with N1 without Postmastectomy Radiotherapy
por: Wen, Ge, et al.
Publicado: (2016)

The effect of postmastectomy radiation therapy on high-risk patients with T1-2N0 breast cancer
por: Luo, Chuanxu, et al.
Publicado: (2021)

Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II–III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy
por: Chen, Xingxing, et al.
Publicado: (2018)

T1-2N1M0 triple-negative breast cancer patients from the SEER database showed potential benefit from post-mastectomy radiotherapy
por: Wang, Xueying, et al.
Publicado: (2020)

The role of chemotherapy in patients with T1bN0M0 triple-negative breast cancer: a real-world competing risk analysis
por: Lan, Tian, et al.
Publicado: (2021)

Clinical decision making in postmastectomy radiotherapy in node negative breast cancer
por: Barrientos, Rodrigo, et al.
Publicado: (2018)

HSulf-1 and palbociclib exert synergistic antitumor effects on RB-positive triple-negative breast cancer
por: Chen, Fengxia, et al.
Publicado: (2020)

The impact of postmastectomy radiotherapy on cT1-2N1 breast cancer patients with ypN0 after neoadjuvant chemotherapy: a retrospective study based on real-world data
por: Dai, Yuran, et al.
Publicado: (2023)

Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis
por: Wu, Chenghui, et al.
Publicado: (2023)

Solid component proportion is an important predictor of tumor invasiveness in clinical stage T(1)N(0)M(0) (cT(1)N(0)M(0)) lung adenocarcinoma
por: Li, Meng, et al.
Publicado: (2018)

Predicting aggressive outcome in T1N0M0 breast cancer
por: Kronqvist, P, et al.
Publicado: (2004)

Effect of postmastectomy radiotherapy on pT(1-2)N(1) breast cancer patients with different molecular subtypes()
por: Guo, Xin-Yuan, et al.
Publicado: (2021)

The Impact of Post-Operative Radiotherapy in Early Stage (pT1-pT2N0M0) Oral Tongue Squamous Cell Carcinoma in Era of DOI
por: Alterio, Daniela, et al.
Publicado: (2021)

Definitive radiotherapy or chemoradiotherapy for distal rectal cancer with early stage of cT1-2N0
por: Peng, Hai-Hua, et al.
Publicado: (2019)

Association of Human Epidermal Growth Factor Receptor 2 with Radiotherapy Resistance in Patients with T1N0M0 Breast Cancer
por: Kim, Hyun-Ah, et al.
Publicado: (2013)

Stage T1N0M0 renal cell carcinoma: the prognosis in Asian patients
por: Zhang, Zhi-Ling, et al.
Publicado: (2011)

The role of postmastectomy radiation in patients with ypN0 breast cancer after neoadjuvant chemotherapy: a meta-analysis
por: Wang, Ke, et al.
Publicado: (2021)

Two-Stage Prosthetic Breast Reconstruction after Mastectomy with or without Prior Postmastectomy Radiotherapy
por: Lam, Thomas C., et al.
Publicado: (2017)

Stereotactic ablative radiotherapy for inoperable T1‐2N0M0 small‐cell lung cancer
por: Tang, Hui, et al.
Publicado: (2022)

The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype
por: Wei, Jinli, et al.
Publicado: (2020)

Effectiveness of intraoperative radiotherapy vs hypofractionated postmastectomy radiotherapy for early stage breast cancer: A protocol for systematic review and meta-analysis
por: Feng, Jiang-Yi, et al.
Publicado: (2021)

Differentiating peripheral cholangiocarcinoma in stages T1N0M0 and T2N0M0 from hepatic hypovascular nodules using dynamic contrast-enhanced MRI
por: Li, Shihong, et al.
Publicado: (2017)

Effect of postmastectomy radiotherapy on triple-negative breast cancer with T1-2 and 1-3 positive axillary lymph nodes: a population-based study using the SEER 18 database
por: Zhang, Jie, et al.
Publicado: (2019)

Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database
por: Wu, Junzhao, et al.
Publicado: (2022)

Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer
por: Kim, Hyun-Ah, et al.
Publicado: (2015)

The Value of the 8th Edition of American Joint Committee on Cancer Pathological Prognostic Staging on the Selection of Postmastectomy Radiotherapy for T1–2N1 Breast Cancer
por: Wang, Jun, et al.
Publicado: (2022)

The Predictive Effect of the 8th AJCC Pathological Prognostic Staging on the Benefit of Postmastectomy Radiotherapy in N2/N3 Breast Cancer
por: Yang, Shi-Ping, et al.
Publicado: (2022)

The relationship between immediate postmastectomy reconstruction modalities and survival benefits in patients with triple negative breast cancer
por: Dai, Luyao, et al.
Publicado: (2022)

Risk factors for axillary lymph node metastases in clinical stage T1-2N0M0 breast cancer patients
por: Zhang, Yuanxin, et al.
Publicado: (2019)

Practical Model to Optimize the Strategy of Adjuvant Postmastectomy Radiotherapy in T1-2N1 Breast Cancer With Modern Systemic Therapy
por: Xu, Fei-Fei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3k884jff4sg5mo0jo41g6rdvv2